"Recent advances in clinical genetic studies of epilepsies have identified a steadily growing number of mutations in new candidate genes, creating a need for an effective approach to rapidly provide functional data as to their in...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
DESIRE
Development and Epilepsy Strategies for Innovative Researc...
16M€
Cerrado
PhenoTECH
Large scale platform for motion detection and fluorescence i...
150K€
Cerrado
EPIMIRNA
MicroRNAs in the Pathogenesis Treatment and Prevention of E...
16M€
Cerrado
EpiEpiNet
Epileptogenesis and Epilepsy Network from genes synapses a...
900K€
Cerrado
MTLE-HS
Genomic sequence variants that correlate with gene expressio...
56K€
Cerrado
BFU2015-66887-R
DISECCION DE LAS REDES EPILEPTICAS DEL LOBULO TEMPORAL: DE L...
327K€
Cerrado
Información proyecto GEMZ
Duración del proyecto: 33 meses
Fecha Inicio: 2018-03-19
Fecha Fin: 2020-12-31
Líder del proyecto
Innovasjon Norge
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
196K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
"Recent advances in clinical genetic studies of epilepsies have identified a steadily growing number of mutations in new candidate genes, creating a need for an effective approach to rapidly provide functional data as to their in vivo function. Furthermore, there is an urgent need to create new, cost- and time-effective animal models which successfully mimic genetic epilepsies in humans, as well as efficient drug discovery approaches to identify compounds useful in the management of these diseases. Here, using established genetic methods, loss- and gain-of-function zebrafish epilepsy models for gene variants recently identified to cause severe, drug-resistant epileptic encephalopathies (EE) will be created. Using a multidisciplinary ""deep-phenotyping"" strategy of pharmacological profiling (i.e. assessment of antiepileptic drugs (AEDs) with known mechanisms of action), high-throughput analysis of locomotor activity and seizure-like behavior, electroencephalographic recordings, histopathological analysis of zebrafish mutant brains, single-cell RNA expression profiling and high-resolution (SPIM) Ca2+ imaging analysis of brain activity, these models will be fully characterized and validated. Finally, a large-scale screen using a library of synthetic small molecules, drug-like natural products and FDA-approved drugs to identify compounds with antiepileptic activity will be performed in one of these models. The main objective of this project is to create and validate new zebrafish models of epilepsy, which will provide both new insights into the mechanisms of epileptogenesis in vivo and indicate potentially novel entry routes for therapeutic intervention."